H.R. 4396 — Uterine Cancer Study Act of 2025

This section directs the Secretary of Health and Human Services (HHS), in coordination with the Commissioner of Food and Drugs (FDA) and the Director of the National Institutes of Health (NIH), to conduct a study on the relationship between chemical hair straighteners and uterine cancer, with a focus on increased incidence among women of color. The study must (1) review findings and recommendations from prior studies; (2) consider impacts on women and other individuals at risk from all racial and ethnic backgrounds; (3) disaggregate results by whether products contain dyes or coloring, bleach, highlights, or perms; and (4) assess whether FDA should impose additional testing requirements on hair straightening product manufacturers. HHS must submit a study methodology to the House Energy and Commerce Committee and Senate Health, Education, Labor, and Pensions (HELP) Committee within 45 days of enactment, commence the study within 180 days of enactment, and submit a report on results to the same committees within two years of enactment.